The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
about
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experienceIbrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinionBruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinibNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewThe tumor microenvironment shapes hallmarks of mature B-cell malignancies.High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomibIbrutinib inhibits SDF1/CXCR4 mediated migration in AMLA road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors.Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis.Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignanciesIncidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.Bortezomib for the treatment of non-Hodgkin's lymphomaCurrent approaches and advance in mantle cell lymphoma treatment.Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemiaIbrutinib for B cell malignancies.Overcoming bortezomib resistance in multiple myeloma.Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma.Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.Novel agents in mantle cell lymphoma.Bortezomib in the treatment of mantle cell lymphoma.Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report.Ibrutinib for mantle cell lymphoma.MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.Targeting protein kinase C in mantle cell lymphoma.Expression and pro-survival function of phospholipase Cγ2 in diffuse large B-cell lymphoma.Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma.Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy.There is life in the old dog yet: thymidine kinase as predictive marker in diffuse large B-cell lymphoma.Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-κB signalling instead of B-cell receptor signalling.BTK suppresses myeloma cellular senescence through activating AKT/P27/Rb signaling.Benzoquinones as inhibitors of botulinum neurotoxin serotype A.Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma.Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop.Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
P2860
Q26738946-897D1831-18B9-4320-A95C-3274028364B8Q26783430-D1EDCF3E-5549-485A-9F1F-55754C12BAA2Q26995113-124FAC51-6701-4A73-8E5A-4FE27AAA4CC3Q27304386-399E6608-39A0-434B-8928-9E2571E4A807Q27687567-D3B0E4DF-837A-4446-A044-12362F73D6BAQ28818948-1C71FF2F-D76C-44D3-8E2B-35A0390113DFQ34042250-71658617-904E-473B-BCFC-4B0FDEB3AE40Q34067085-7D9B2BDA-0A6B-4BDF-BA44-64604D8DB23FQ34722000-09A1A6CB-A06C-4DDC-9B3B-04594A950628Q35723777-75FAB394-0DC1-4D25-8A70-C8CB48D48CE7Q36183770-A7672ADA-9A68-4601-9329-917BFF57CAD3Q36334833-50E02186-783E-4B88-BA2C-90207CACCAB4Q36337598-454F62A8-3E4B-4D90-A7DA-68E7E837A1A7Q36548443-E9DE2223-5973-48B5-B795-10FDE14777B7Q36868056-671CE9FD-E248-4856-BC99-6FE95DE97695Q37044078-2EDD58E0-64CF-45F2-B3C7-CDB25F9D52A4Q37109671-658AFD5F-8AD3-40F0-9D26-CA88CAAD47A7Q37180382-37834BF6-9414-4336-83C2-30F907A1701EQ37555418-E692239B-10B2-4C29-9EA5-A3BB234F726FQ38238610-B6965DCC-7CB6-4EFA-811F-3E98004ADE74Q38311896-3AF6CB95-1C58-4650-BB7D-1751B5B62F62Q38351184-53257666-6625-4116-8614-39570E4A04FBQ38516704-2CF21F55-1F29-42BF-98B5-A1A2A7493991Q38582650-789EADE9-8834-4498-BA15-24A88533B57BQ38675161-CBC535A1-F8CF-48BE-936C-14C6EC41155AQ38687541-88D17D72-7407-4288-91B3-AEB713CFD388Q38694168-DB92F9A4-E736-47F8-AAB8-689E216D4394Q38714023-D9A91315-45C6-4F00-B37A-79F5815CBE4CQ38791124-3EE89CE9-1B6D-41DA-8B7B-9B257D16C523Q38976449-6BE68B74-D290-495D-B97A-C9840A391839Q39031250-2CE83272-0FBD-420F-8D02-77BA21F3A7AAQ39147488-425DB09C-8466-43A4-8D94-5F12B609BEACQ39586919-ECF67438-1722-419C-9C43-62B3DB1F618CQ40821648-9CFAD9BE-002A-4CCB-A75F-2AC777722C76Q41344360-C029CB86-B88D-4420-9002-4A58B06BBB75Q41902457-CD68236D-D605-4A37-B7F4-5F672D935A06Q42553000-950042D2-F940-4067-BCCE-71BEAEC5CC67Q42710884-C6133BCC-6B10-4F25-9D05-02ADF021950DQ49036164-55FE37AB-F4CD-4DD3-A28D-0F73438FCFC2Q51072600-0B503EBD-2585-4DCF-AF91-6E3D237A998E
P2860
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 January 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The Bruton tyrosine kinase (BT ...... ve or resistant to bortezomib.
@en
The Bruton tyrosine kinase
@nl
type
label
The Bruton tyrosine kinase (BT ...... ve or resistant to bortezomib.
@en
The Bruton tyrosine kinase
@nl
prefLabel
The Bruton tyrosine kinase (BT ...... ve or resistant to bortezomib.
@en
The Bruton tyrosine kinase
@nl
P2093
P2860
P356
P1476
The Bruton tyrosine kinase (BT ...... ve or resistant to bortezomib.
@en
P2093
Girija Dasmahapatra
Hiral Patel
Jonathan Friedberg
Richard I Fisher
Steven Grant
P2860
P356
10.1111/BJH.12206
P407
P50
P577
2013-01-30T00:00:00Z